
In the Phase 3 VIVID-1 trial, patients treated with mirikizumab experienced significant improvement in clinical remission and endoscopic response at …

Eli Lilly has announced that the US Food and Drug Administration (FDA) has approved Omvoh (mirikizumab-mrkz) infusion (300mg/15mL)/injection (100mg/mL) for …
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions

